Latest News
NFL Biosciences secures regulatory approval to launch Phase 2 trial of NFL-102
22 October 2026 - French biopharmaceutical company NFL Biosciences (Euronext Growth Paris:ALNFL) announced on Thursday that has received approval from France's National Agency for Medicines and Health Products Safety (ANSM) and the Committee for...
ProBio's Nanjing biologics manufacturing facility completes Chinese regulatory pre-approval inspection
22 October 2026 - ProBio Inc, a China-based global contract research, development and manufacturing organisation (CRDMO), announced on Wednesday the successful completion of a Pre-Approval Inspection (PAI) by China's National Medical Products Ad...
Lynch Regenerative Medicine's Phase IIb clinical trial of rhPDGF-BB injection cleared by FDA
22 October 2026 - Regenerative aesthetics company Lynch Regenerative Medicine LLC (LRM) announced on Wednesday that its Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating injectable recombinant human platelet-derived g...
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
21 October 2026 - Swiss pharmaceutical company Novartis AG (SIX: NOVN; NYSE: NVS) on Wednesday said the European Commission has approved Cosentyx (secukinumab) for adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucoc...
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
21 October 2026 - Edwards Lifesciences Corporation (NYSE: EW), a structural heart innovation company, announced on Wednesday that it has received US Food and Drug Administration (FDA) approval for its PASCAL Precision system to repair the tricuspid v...